Biotech | March 18, 2022
Sanofi moves forward with EUROAPI listing on Euronext Paris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
Govt announces vaccination programme for kids and those above 60 years of age
It is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Routine tests undertaken by women dropped by 35% in 2020
Subscribe To Our Newsletter & Stay Updated
